Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results
Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2020.
“Gilead continues to play a central role in the pandemic, with Veklury now treating one in two hospitalized patients in the United States. At the same time, we continue to meet the needs of people living with HIV, cancer, viral hepatitis and other conditions,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “As we head into 2021, we have many additional opportunities to help patients, especially in oncology where Trodelvy, for example has the potential to treat a broad range of cancer types. These new opportunities, together with our continued leadership in antivirals put Gilead on a clear path to growth.”
Financial Results
|
|
Three Months Ended |
|
|
|
Twelve Months Ended |
|
|
||||||||||||
|
|
December 31, |
|
|
|
December 31, |
|
|
||||||||||||
(In millions, except percentages, per share amounts) |
|
2020 |
|
2019 |
|
Change |
|
2020 |
Gilead Sciences Inc
NASDAQ:GILDGILD RankingsGILD Latest NewsGILD Latest SEC FilingsJul 14, 2025
[144] Gilead Sciences Inc SEC Filing
Jun 30, 2025
[144] Gilead Sciences Inc SEC Filing
GILD Stock Data
139.05B
1.24B
0.11%
89.78%
1.81%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
FOSTER CITY
| |||||||||||